Sue Sutter explains how the US Food and Drug Administration's handling of issues around protein content differences, statistical analyses of quality data and immunogenicity testing for Sandoz's Zarxio may prove instructive for future 351(k) applicants.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?